Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

DARA: Next Steps After Awarding Of Orphan Designation For KRN5500

On February 25, 2014, DARA BioSciences, Inc. (DARA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to KRN5500 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics. This is enormously positive news for the company. DARA first filed the ODD application back in November 2012, so it's been fifteen long months of back-and-forth with the agency over the iterative process. We most recently wrote about the potential for DARA to receive ODD on KRN5500 in December 2013, calling the designation a potential game-changer for the company. Below we provide some background on KRN5500 and outline how ODD helps greatly improve economic value of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details